Stryker Corporation $SYK Shares Purchased by Waverly Advisors LLC

Waverly Advisors LLC grew its holdings in shares of Stryker Corporation (NYSE:SYK) by 3.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 45,828 shares of the medical technology company’s stock after buying an additional 1,627 shares during the quarter. Waverly Advisors LLC’s holdings in Stryker were worth $15,059,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in SYK. Sankala Group LLC acquired a new position in shares of Stryker during the 4th quarter valued at $26,000. Godfrey Financial Associates Inc. purchased a new position in Stryker in the fourth quarter valued at about $26,000. United Financial Planning Group LLC purchased a new position in Stryker in the third quarter valued at about $27,000. Atlas Capital Advisors Inc. acquired a new position in shares of Stryker during the fourth quarter worth about $27,000. Finally, DJE Kapital AG purchased a new stake in shares of Stryker in the fourth quarter worth about $28,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling

In other news, VP M Kathryn Fink sold 3,500 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $283.45, for a total value of $992,075.00. Following the completion of the sale, the vice president owned 177 shares of the company’s stock, valued at approximately $50,170.65. The trade was a 95.19% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the sale, the director owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This trade represents a 13.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 323,264 shares of company stock worth $100,659,489. Insiders own 4.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Needham & Company LLC dropped their target price on Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Argus set a $370.00 price objective on shares of Stryker in a research note on Thursday, July 9th. Robert W. Baird set a $385.00 target price on shares of Stryker in a research report on Friday, May 1st. BTIG Research set a $371.00 target price on shares of Stryker in a research note on Monday, July 13th. Finally, BMO Capital Markets initiated coverage on shares of Stryker in a report on Wednesday, July 8th. They set an “outperform” rating and a $369.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $392.52.

Stryker Trading Up 0.1%

Shares of SYK opened at $330.69 on Monday. Stryker Corporation has a one year low of $281.00 and a one year high of $404.14. The stock has a 50-day moving average price of $314.69 and a 200 day moving average price of $335.57. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The company has a market capitalization of $126.78 billion, a P/E ratio of 38.27, a P/E/G ratio of 2.12 and a beta of 0.77.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The business had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. During the same quarter in the prior year, the firm earned $2.84 earnings per share. Stryker’s revenue for the quarter was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Sell-side analysts forecast that Stryker Corporation will post 14.99 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s payout ratio is 40.74%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.